Global Health Challenges Spur Vaccine Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Global Health Challenges Spur Vaccine Development
Manufacturers fund research and reduce prices to tackle diseases.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 28-36

Manufacturing challenges

While policymakers wrestle with cost and access issues, manufacturers still face difficulties ensuring the quality of vaccine production. One reason for low utilization of Merck's Zostavax vaccine for shingles has been supply shortages due to manufacturing problems at Merck's West Point, Pennsylvania, vaccines plant; reports of charred particles in vials have further complicated remedial efforts. Merck's adult vaccines for hepatitis A and hepatitis B also are in short supply, and the company has stopped producing its ProQuad varicella-MMR vaccine.

Indian manufacturers seeking to ramp up production of low-cost vaccines also have run into production problems. WHO recently removed combination vaccines produced by Panacea Biotech from its pre-qualification list due to inspections that found quality management deficiencies at the firm's plant near Punjab, India.

Meanwhile, FDA has concerns about manufacturing deficiencies and particulate contamination at several vaccine companies. FDA sent a Warning Letter to Australia-based influenza `dicated that the company had not addressed manufacturing problems identified at a site visit in April 2010. The initial FDA investigation stemmed from adverse-event reports citing reports of fever and convulsions in children taking its influenza vaccine in during the 2009–2010 pandemic, but uncovered a number of deficiencies in recordkeeping and quality control.

The challenges of ensuring vaccine safety and quality were illustrated in 2010 when FDA suspended the marketing of GSK's rotavirus vaccine, Rotarix, for several months to assess the effect of adventitious porcine virus found in this product. After evaluation, FDA recommended that physicians continue to use Rotarix, as well as Merck's Rota Teq vaccine, which has a similar problem. The agency cited strong safety records for the products and no evidence that the viruses pose a safety risk to humans. The case points to difficulties in adopting advanced analytic technologies that can uncover previously undetectable contaminants. The challenge for regulators is to weigh the risk of halting vaccination for a dangerous health condition against uncertain effects of apparently benign extraneous viral material.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,
.

References

1. B. Deer, British Medical Jrnl., Jan. 5, 2011 and Jan. 19, 2011.

2. A. Wakefield, The Lancet, 35, 637–641 (1998).

3. Editorial Retraction, The Lancet, Feb. 2, 2010.

4. IOM,Adverse Effects of Vaccines (Washington, DC, 2011), http://www.iom.edu/vaccineadverseeffects/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here